Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biosimilars Debate Heats up over Cost Savings, Safety Concerns

Susan Bernstein  |  Issue: April 2016  |  April 15, 2016

Seemingly minor changes in formulation can cause major adverse effects. When a stabilizing agent in Eprex, a biosimilar of epoetin alfa used for treating anemia that’s approved outside the U.S., was changed, it led to pure red cell aplasia (PRCA) in some patients.1

“It’s very important to understand that a biosimilar agent will never be identical, at a molecular level, to its reference drug,” said Douglas W. White, MD, a rheumatologist at Gundersen Health System in Onalaska, Wis. “Variations inherent in the manufacture of biosimilars can result in highly divergent responses in humans, especially with respect to immunogenicity, as we saw with Eprex. So we want safeguards in place to minimize such a possibility and to maximize our chances of catching it early should something go wrong.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although Dr. Daikh has confidence that pharmaceutical companies with experience in developing biologics will maintain high-quality control, “it will be incumbent upon the FDA to ensure that all biosimilars are manufactured to the same quality and purity standards applied to the parent drugs, regardless of where and by whom the biosimilars are produced.”

The ACR strongly suggests the following standards for biosimilars, Dr. Worthing testified:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Long-term post-marketing studies of approved biosimilars to monitor for adverse events;
  • Distinct names for each biosimilar to ensure correct prescribing and dispensing, as well as monitoring and tracking; and
  • Clear FDA labeling that indicates whether a drug is: a) a biosimilar or interchangeable product; b) lists all approved indications for the biosimilar; and c) specifies whether clinical data come from studies of the biosimilar or the reference biologic.

Currently, U.S. biosimilars will each have a four-letter suffix to identify their reference biologic, instead of a distinct brand name. Some rheumatologists fear this naming style will cause confusion.

“We need to be able to confidently prescribe these therapies to our patients and feel comfortable that proper mechanisms are in place for rheumatologists to monitor patient reactions to prescribed biosimilars,” said Dr. Worthing. “Rheumatologists have been working with biologics for quite some time, and our patients take them for lengthy periods of time to manage their conditions, so we have a unique understanding of the extreme complexities of these medications.”

The pharmaceutical industry also wants the new products to have memorable, meaningful names, said Geoff Eich, executive director, Amgen Biosimilars.

“It will be more accurate in the database if you can actually remember it and track any adverse events to the appropriate product,” said Mr. Eich. He’s optimistic that biosimilars will encourage robust competition that will fuel innovation. “There’s opportunity for biosimilars around the world to be very successful.”

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:Biologics/DMARDsDrug UpdatesLegislation & Advocacy Tagged with:BiologicsBiosimilarscost savingdebatedrugFDApatient careRheumatic DiseaserheumatologySafetyTreatment

Related Articles

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences